Skip to content

Viking Therapeutics

US · VKTX #2352 by market cap Listed 2015
24.77 -1.07 -4.14%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:56

Valuation each multiple against its own 5-year range

P/B ratio 6.33 Expensive vs history 68th percentile
5-year average 5.90 · #416 of 514 in Biotechnology
P/E ratio -5.39 Expensive vs history 81st percentile
5-year average -22.87 · forward -5.30
P/S ratio --
5-year average 0.00

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
Viking Therapeutics (VKTX) 3.16B -4.57 5.37 0.00%
Vertex Pharmaceuticals (VRTX) 130.58B 33.14 6.25 0.00%
Regeneron Pharmaceuticals (REGN) 95.24B 20.35 2.84 0.40%
Moderna (MRNA) 78.90B -27.70 11.54 0.00%
argenx SE (ARGX) 58.21B 32.06 6.92 0.00%
BeiGene (ONC) 44.66B 49.74 7.67 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value42.82 Economic moatNone UncertaintyVery High

Trading 72.9% below Morningstar's fair value estimate.

Fair value

Viking Therapeutics Inc earns a 3-star quantitative star rating, indicating our belief that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 32% discount to our quantitative fair value estimate of $42.81 per share; however, caution is warranted due to this estimate's very high uncertainty rating.

The company's liquidity strengthens our quantitative valuation. Adequate liquidity allows a company to meet short-term obligations, enhancing financial stability and reducing distress risk. Reflecting the firm's liquidity is its median trading volume over the past 60 days, which lies in the top 20% globally. Trading volumes are high on shares, which may indicate increased institutional interest in stock ownership. We believe this is a sign that shares could be cheap.

On a different note, the company's valuation metrics are potentially concerning. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's book value yield of 17.2%, a core component of valuation, sits in the bottom 20% globally. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which, despite our favorable price/fair value ratio, is a negative attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance bodes well for future returns in light of other contributors to our model.

Economic moat

With its quantitative economic moat rating of none, we do not expect this company to materially outearn its cost of capital in the long run. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 19:56:05 · For reference only, not investment advice and not tailored to your situation.

Viking Therapeutics discussion 0 comments

Add a comment